LIXIANA FILM-COATED TABLET 60 MG

País: Cingapura

Língua: inglês

Origem: HSA (Health Sciences Authority)

Ingredientes ativos:

EDOXABAN TOSILATE eqv. EDOXABAN

Disponível em:

A. MENARINI SINGAPORE PTE. LTD.

Código ATC:

B01AF03

Forma farmacêutica:

TABLET, FILM COATED

Composição:

EDOXABAN TOSILATE eqv. EDOXABAN 60 mg

Via de administração:

ORAL

Tipo de prescrição:

Prescription Only

Fabricado por:

Daiichi Sankyo Europe GmbH (Bulk manufacturer & primary packager)

Status de autorização:

ACTIVE

Data de autorização:

2020-12-18

Características técnicas

1
LIXIANA
SINGAPORE PACKAGE INSERT
1.
NAME OF THE MEDICINAL PRODUCT
Lixiana 15 mg film-coated tablets
Lixiana 30 mg film-coated tablets
Lixiana 60 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Lixiana 15 mg film-coated tablets
Each 15 mg film-coated tablet contains 15 mg edoxaban (as tosilate).
Lixiana 30 mg film-coated tablets
Each 30 mg film-coated tablet contains 30 mg edoxaban (as tosilate).
Lixiana 60 mg film-coated tablets
Each 60 mg film-coated tablet contains 60 mg edoxaban (as tosilate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Lixiana 15 mg film-coated tablets:
Orange, round-shaped film-coated tablets (6.7 mm diameter) debossed
with “DSC L15”.
Lixiana 30 mg film-coated tablets:
Pink, round-shaped film-coated tablets (8.5 mm diameter) debossed with
“DSC L30”.
Lixiana 60 mg film-coated tablets:
Yellow, round-shaped film-coated tablets (10.5 mm diameter) debossed
with “DSC L60”.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Lixiana is indicated in prevention of stroke and systemic embolism in
adult patients with nonvalvular
atrial fibrillation (NVAF) with one or more risk factors, such as
congestive heart failure, hypertension,
age ≥ 75 years, diabetes mellitus, prior stroke or transient
ischaemic attack (TIA).
Lixiana is indicated in treatment of deep vein thrombosis (DVT) and
pulmonary embolism (PE), and
for the prevention of recurrent DVT and PE in adults (see section 4.4
for haemodynamically unstable
PE patients).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Prevention of stroke and systemic embolism _
The recommended dose is 60 mg edoxaban once daily.
Therapy with edoxaban in NVAF patients should be continued long term.
2
_Treatment of DVT, treatment of PE and prevention of recurrent DVT and
PE (VTE) _
The recommended dose is 60 mg edoxaban once daily following initial
use of parenteral anticoagulant
for at least 5 days (see section 5.1). Edoxaban and initial parenteral
anticoagulant should not be
admin